CRA assessed commercial efforts to develop and commercialize a MS drug with respect to obligations stemming from the acquisition of Genzyme Corporation by Sanofi-Aventis following shareholder concerns. In particular, CRA assessed the development strategy for the drug, including an assessment of its launch market access strategy and pricing strategy in various countries in the context of the drug’s attributes and existing available treatments. Further, CRA assessed Plaintiff theories of appropriate commercialization in connection with the achievement of contingent milestones associated with commercial sales.
Were shareholders harmed by Senate Bill 21’s amendments to the Delaware General Corporation Law?
Delaware Governor Meyer signed into law Senate Bill 21 (SB21) in March 2025, updating Delaware’s corporate law, with some of the key provisions including safe...